"We work closely with our partners through R&D to develop optimized products that are meeting our partners' and Neptune's rigorous quality standards," said Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "According to our partnership and pipeline strategy, we continue to work with other industry leaders on new product opportunities which will lead to further alliances in the future," she added.
Croda is a global leader in specialty chemicals sold to a wide range of industries with total annual sales of over $1,8 billion. The Croda Health Care division provides high quality ingredients for nutritional and pharmaceutical markets with particular expertise in specialty lipids. Many Croda Health Care products are supported by extensive clinical trials that demonstrate their safety and efficacy for pharmaceutical applications. Croda offers omega-3 and 6 essential fatty acid concentrates for the prevention and treatment of cardiovascular, dermatological, immunological and neurological conditions.
Croda manufactures the industry leading Incromega(TM) range, a new generation of omega-3 marine oil concentrates that offer enhanced potency, purity and efficacy for specific conditions. The lipids are concentrated and purified to pharmaceutical grade requirements using proprietary PureMax(TM) technology selectively concentrating the key fatty acid actives, EPA, DPA and DHA.
Neptune researches and develops proprietary bioactive ingredients and
products for nutraceutical, medical food and pharmaceutical applications.
Through clinical research, Neptune is showing the clinical benefits of its
products in various therapeutic indications with a
|SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.|
Copyright©2008 PR Newswire.
All rights reserved